$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
转移性结直肠癌患者可服用瑞格非尼或者TAS-102
2025-10-19 11:44:20
Check Details
瑞格非尼降低治疗转移性结直肠癌死亡风险
2025-10-19 11:44:20
Check Details
结直肠癌患者服用索拉非尼发生疾病进展后可服用瑞格非尼
2025-10-19 11:44:20
Check Details
瑞戈非尼耐受性的真实数据格外重要
2025-10-19 11:44:20
Check Details
瑞戈非尼的治疗数据以及安全性
2025-10-19 11:44:20
Check Details
转移性结直肠癌服用靶向药物瑞戈非尼的临床结果
2025-10-19 11:44:20
Check Details
难治性结直肠癌患者服用瑞格非尼可达到最高的有效性
2025-10-19 11:44:20
Check Details
结直肠癌患者在哪种情况先必须停止服用瑞格非尼
2025-10-19 11:44:20
Check Details
肝脏毒属性是直肠癌患者需要着重注意的事项之一
2025-10-19 11:44:20
Check Details
瑞格非尼诱导的转移性胃肠道间质瘤患者重度肝损伤:免疫抑制剂可以改善
2025-10-19 11:44:20
Check Details
服用瑞格非尼需要定期检测肝肾功能、血常规
2025-10-19 11:44:20
Check Details
瑞格非尼治疗经治结直肠癌患者的预后临床因素:对临床管理的影响
2025-10-19 11:44:20
Check Details
1
2
...
1590
1591
1592
1593
1594
1595
1596
...
4154
4155
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
FDA Accelerates Approval of Zongertinib: Precision Medicine Advancement for HER2-Mutated NSCLC
2
Sotorasib (Lumakras®): The First KRAS Inhibitor Revolutionizing Non-Small Cell Lung Cancer Treatment
3
LONSURF® (Trifluridine/Tipiracil): Unveiling the Global R&D and Supply Chain Behind the Oral Chemotherapy
4
FDA Approves Lilly's Inluriyo (Imlunestrant) for ESR1-Mutant Advanced Breast Cancer
5
Tivozanib: The Evolution of Highly Selective VEGFR Inhibition in Renal Cell Carcinoma
6
Trifluridine/Tipiracil: Managing Side Effects in Metastatic Colorectal and Gastric Cancer
7
Adagrasib Medication Management Guide for Special Populations
8
Olutasidenib (Rezlidhia): A Targeted Drug for IDH1-Mutated Relapsed/Refractory AML
9
Capmatinib Redefines Precision Therapy for MET-Mutated Lung Cancer
10
Cabozantinib: Pivotal Advancements and Global Implications in Multi-Cancer Treatment with Multi-Kinase Inhibition
11
Tucatinib (Tukysa): A Precision Medicine for HER2-Positive Breast & Colorectal Cancer
12
Global Breakthrough: Pralsetinib - Precision Medicine for RET Mutation-Driven Cancers